natgillin/translations-raw huggingface dataset:
parsing the signal frame from the demodulated broadcasting signal, wherein the signal frame includes preamble symbols and symbols of Physical Layer Pipe, PLP, data, wherein the preamble symbols include at least one Layer 1, L1, Time interleaving, TI, block and L1 header in front of the at least one L1 TI block, wherein the at least one L1 T1 block and L1 header are repeated in a preamble symbol, wherein the L1 header includes the L1 TI mode information indicating the time deinterleaving depth of the L1 signaling data; 
raščlanjivanje okvira signala iz demoduliranog okvira signala, pri čemu okvir signala uključuje simbole početnog niza i simbole podatkovnih rezova s podacima cijevi fizičke razine, PLP, pri čemu simboli početnog niza uključuju blokove razine 1, L, 1i svaki od L1 blokova ima najmanje L1, blok umetanja vremena, TI,i L1 zaglavlje ispred najmanje jednog L1 TI bloka, pri čemu se najmanje L1 TI blok i L1 zaglavlje ponavljaju u simbolu početnog niza, pri čemu zaglavlje L1 uključuje informaciju oblika L1 TI koja ukazuje dubinu raspletanja vremena signalnog podatka L1;
inner decoding the L1 signaling data by a Low Density Parity Check, LDPC coding scheme and outer decoding the inner decoded L1 signaling data by a Bose-Chadhuri-Hocquenghem, BCH, coding scheme; 
unutarnje dekodiranje PLP podataka shemom kodiranja provjere pariteta niske gustoće; i vanjsko dekodiranje vanjsko dekodiranih PLP podataka pomoću sheme kodiranja Bose-Chadhuri-Hocquenghem, BHC.
means (r308-1) for selectively time-deinterleaving the preamble symbols including the at least one L1 TI block by a row-column twisted fashion, wherein the row-column twisted fashion comprises input L1 signaling data cells serially written into an interleaving memory in a diagonal direction, and serially read out row-wise, without considering pilot positions; 
sredstvo (r308-1) za selektivno raspletanje vremena simbola početnog niza uključujući barem jedan TI blok na način prelamanja redova-stupaca, pri čemu način prelamanja redova-stupaca obuhvaća unos u podatkovne stanice signalnih podataka L1 serijski upisane u memoriju umetanja u dijagonalnom smjeru, i serijsko očitavanje u smjeru redova, bez razmatranja pozicija pilota;
means (r303-1) for inner decoding the L1 signaling data by Low Density Parity Check, LDPC, coding scheme and means (r301-1) for outer decoding the inner decoded L1 signaling data by a Bose-Chadhuri-Hocquenghem, BCH, coding scheme; 
sredstvo (r303) za unutarnje dekodiranje PLP podataka shemom kodiranja provjere pariteta niske gustoće, LDPC; i sredstvo (r301) za vanjsko dekodiranje PLP podataka pomoću sheme kodiranja Bose-Chadhuri-Hocquenghem, BHC.
characterised in that the cutting means (150,151) are integrated into the inhaler body (100) and formed of the same material and manufactured in the same unitary step such that the inhaler is formed of only two operating components. 
naznačen time da su sredstva za sječenje (150,151) integrirana u tijelo inhalatora (100) i oblikovana su od istog materijala, te su proizvedena u istom jedinstvenom koraku tako da je inhalator konstruiran od samo dvije radne komponente.
A dry powder inhaler according to claim 1, wherein the body (100) and cutting means (150,151) are formed by a unitary moulding operation. 
Inhalator suhog praha prema zahtjevu 1, naznačen time da su tijelo (100) i sredstva za sječenje (150,151) oblikovani u jedinstvenoj operaciji prešanja.
A dry powder inhaler according to claim 5, wherein each blade has a double curved cross-section. 
Inhalator suhog praha prema zahtjevu 5, naznačen time da je svaka lopatica dvostruko zakrivljena u presjeku.
A dry powder inhaler according to claim 10, wherein the textured finish is present on the outer surface of both walls (160) of the capsule tray (110). 
Inhalator suhog praha prema zahtjevu 10, naznačen time da se na vanjskoj površini obje stjenke (160) ladice za kapsulu (110) nalazi teksturirana obrada.
A dry powder inhaler according to claim 10 or claim 11, wherein the or each textured surface has one of a pattern of ridges, channels or hemi-spherical projections formed thereon. 
Inhalator suhog praha prema zahtjevu 10 ili zahtjevu 11, naznačen time da inhalator ili svaka strukturirana površina na sebi ima formiran jedan uzorak grebena, kanala ili polu-kuglastih izbočina.
A dry powder inhaler according to claim 12, wherein the or each textured surface has a plurality of parallel ridges which are obliquely inclined to the edges of the capsule tray. 
Inhalator suhog praha prema zahtjevu 12, naznačen time da inhalator ili svaka strukturirana površina ima mnoštvo paralelnih hrptova koji su nepravocrtno nagnuti prema rubovima ladice za kapsulu.
C1-6 alkoxy, optionally substituted with one to five fluorines; 
-6 alkoksi, izborno supstituiran sa jednim do pet fluora;
C1-10 alkyl, wherein alkyl is optionally substituted with one to five substituents independently selected from fluorine and hydroxy, 
-10 alkil, gdje je alkil izborno supstituiran sa jednim do pet supstituenata nezavisno izabranih od fluora i hidroksi,
The combination of Claim 1 wherein Ar is 2,5-difluorophenyl or 2,4,5-trifluorophenyl. 
Spoj prema patentnom zahtjevu 2, naznačen time što je Ar jednako 2,5-difluorofenil ili 2,4,5-trifluorofenil.
The combination according to claim 10 for use in the treatment of insulin resistance, hyperglycemic or type 2 diabetes. 
Spoj prema patentnom zahtjevu 1 za uporabu u liječenju insulinske rezistencije, hiperglikemije ili dijabetesa tipa 2.
A method of producing a stable freeze-dried composition having an amorphous structure and comprising the peptides of SEQ ID NOS: 1 to 4, said method comprising: 
Postupak proizvodnje stabilnog liofiliziranog pripravka koji sadrži peptide SEQ ID Br.: 1 do 4, naznačen time, da se rečeni postupak sastoji od:
is phenyl, acyl, or heteroaryl wherein the phenyl and heteroaryl are optionally substituted with 1, 2, 3, 4, or 5 R9 groups; 
je fenil, acil, ili heteroaril, gdje su fenil i heteroaril izborno supstituirani sa 1, 2, 3, 4 ili 5 R9 grupa;
A method for preventing or treating plant infections by fungi or oomycetes comprising the application of an effective amount of Vitis vinifera seeds extract on the plant to be treated. 
Metoda prevencije ili liječenja infekcije biljaka od gljivica ili Oomycetes, naznačena time da obuhvaća izlaganje biljke koju valja liječiti učinkovitoj količini ekstrakta sjemenki.
A method according to claim 4 wherein the plant is Vitis vinifera . 
Metoda prema patentnom zahtjevu 4, naznačena time da biljka jest Vitis vinifera.
The acylthiourea compound according to claim 1 or a salt thereof, wherein R1 is a hydrogen atom or a C1-3 alkyl group; R2 is a hydrogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted C6-14 aromatic hydrocarbon group, or an optionally substituted saturated or unsaturated heterocyclic group, or R1 and R2 may form, together with the nitrogen atom to which they are attached, an optionally substituted saturated nitrogen-containing heterocyclic group; R3 is a C1-3 alkyl group; R4 is a halogen atom; and each of R5 and R6, which are the same or different, is a hydrogen atom, a halogen atom, a C1-3 alkyl group which may have a halogen atom as a substituent or C1-3 alkoxy group. 
Spoj aciltiouree prema zahtjevu 1 ili njegova sol, naznačen time što R2 je atom vodika, po izboru supstituirani C1-6 alkil skupinu, po izboru supstituirani C6-14 aromatski ugljikovodik skupinu, ili opcijski supstituiran zasićeni ili nezasićeni heterociklički skupinu, ili R1 i R2 mogu formirati, zajedno s atomom dušika na kojeg su vezani, po izboru supstituirani zasićeni koja sadrži dušik heterociklička skupina, R3 je C1-3 alkil, a svaki od R5 i R6, koji su isti ili različiti, je atom vodika, atom halogena, C1-3 alkil skupina koja može imati atom halogena kao supstituentom ili C1-3 alkoksi skupina. Spoj aciltiouree prema zahtjevu 1 ili njegova sol, naznačen time, da je atom vodika ili metil skupina;
The acylthiourea compound according to claim 1 or a salt thereof, wherein R1 is a hydrogen atom; R2 is a C1-6 alkyl group which may have a substituent, said substituent being a hydroxyl group, a C3-10 cycloalkyl group, an optionally substituted C1-6 alkoxy group, an optionally substituted C1-6 alkylamino group, a C1-6 alkanoylamino group, a C1-6 alkylsulfonyl group, an optionally substituted C6-14 aromatic hydrocarbon group, an optionally substituted saturated or unsaturated heterocyclic group, an optionally substituted saturated or unsaturated heterocyclic-carbonyl group, an optionally substituted C1-6 alkylaminocarbonyl group, or an optionally substituted saturated or unsaturated heterocyclic-carbonyl group; R3 is a methyl group; R4 is a fluorine atom or a chlorine atom; R5 is a hydrogen atom; and R6 is a hydrogen atom, a fluorine atom, or a chlorine atom. 
Spoj aciltiouree prema zahtjevu 1 ili njegova sol, naznačen time, da je R1 atom vodika, R2 je C1-6 alkil skupina koja može imati supstituent, a navedeni supstituent je hidroksil skupina, C3-10 cikloalkilna skupina, po izboru supstituirana C1-6 alkoksi skupina, po izboru supstituirana C1-6 alkilamino skupina, C1-6 alkanoilamino skupina, C1-6 alkilsulfonil skupina, po izboru supstituirana C6-14 skupina aromatskih ugljikovodika, po izboru supstituirana zasićena ili nezasićena heterociklička skupina, supstituirana zasićena ili nezasićena heterociklička-karbonil skupina, po izboru supstituirana C1-6 alkilaminokarbonil skupina, ili po izboru supstituirana zasićena ili nezasićena heterociklička-karbonil skupina, R3 je metil skupina, R4 je atom fluora ili atom klora, R5 je atom vodika, a R6 je atom vodika, atom fluora ili atom klora .
The acylthiourea compound according to claim 1 or a salt thereof, wherein R2 is a C1-4 alkyl group which may have a substituent, said substituent being a hydroxyl group, a cyclohexyl group, a C1-3 alkoxy group, a C1-6 alkylamino group, an acetylamino group, a methylsulfonyl group, a phenyl group, a 5- to 7-membered heterocyclic group having 1 to 4 nitrogen and/or oxygen atom(s), a C1-6 alkylaminocarbonyl group, or a 5-to 7-membered heterocyclic-carbonyl group having 1 or 2 nitrogen and/or oxygen atom(s), wherein said C1-3 alkoxy group may further have a hydroxyl group as a substituent; said C1-6 alkylaminocarbonyl group may further have as a substituent a hydroxyl group or a C1-6 alkoxy group; said heterocyclic group may further have as a substituent a C1-6 alkyl group or an oxo group; and said heterocyclic-carbonyl group may further have a C1-6 alkyl group as a substituent, said C1-6 alkyl group optionally having a halogen atom or a hydroxyl group. 
Spoj aciltiouree prema zahtjevu 1 ili njegova sol, naznačen time, da je R2 C1-4 alkil skupina koja može imati supstituent, a navedeni supstituent je hidroksil skupina, cikloheksilna skupina, C1-3 alkoksi skupina, C1-6 alkilamino skupina, acetilamino skupina, metilsulfonil skupina, fenil skupina, 5- do 7-članu heterocikličku skupinu koja ima od 1 do 4 dušika i/ili atom(a) kisika, C1-6 alkilaminokarbonil skupinu, ili 5- do 7- članu heterocikličnu-karbonil skupinu s 1 ili 2 dušika i/ili atom(a) kisika, pri čemu navedene C1-3 alkoksi skupine mogu dodatno imati hidroksilnu skupinu kao supstituent; navedena C1-6 alkilaminokarbonil skupina dodatno može imati kao supstituent hidroksilnu skupinu ili C1-6 alkoksi skupina; navedena heterociklička skupina dodatno može imati kao supstituent C1-6 alkil ili okso skupinu; a navedena heterociklička-karbonil skupina dodatno može imati C1-6 alkil skupinu kao supstituent, pri čemu C1-6 alkil skupina po izboru može imati atom halogena ili hidroksilnu skupinu.
The acylthiourea compound according to claim 1 or a salt thereof, which is selected from the group consisting of: 
Spoj aciltiouree u skladu s patentnim zahtjevom 1 ili njegova sol, naznačen time, da je odabran iz skupine koju čine:
An indolizine derivative represented by the formula (I): wherein 
Derivat indolizina predstavljen formulom (I):
represents any of the following (1) to (7): 
predstavlja bilo što od sljedećeg (1) do (7):
n represents an integral number from 0 to 3, and when n is 2 or 3, these R2 are optionally different from each other; and when two R2 bound to the neighboring atoms in the indolizine ring exist and independently represent a group selected from the group consisting of C1-6 alkyl which may be substituted by a fluorine atom and C1-6 alkoxy which may be substituted by a fluorine atom, these two R2 optionally form a 5 to 8-membered ring together with the binding atoms in the indolizine ring; 
n predstavlja cijeli broj od 0 do 3, i kada n je 2 ili 3, ti R2 su po izboru različiti jedan od drugoga; i kada u indolizinskom prstenu postoji veza dva R2 sa susjednim atomima i nezavisno predstavljaju skupinu izabranu iz grupe koja obuhvaća C1-6 alkil koji može biti supstituiran atomom fluora i C1-6 alkoksi koji može biti supstituiran atomom fluora, ta dva R2 po izboru formiraju 5 do 8-eročlani prsten zajedno s veznim atomima u indolizinskom prstenu;
R1a represents a hydrogen atom, a fluorine atom, a hydroxy group, amino, methyl or trifluoromethyl; 
a predstavlja atom vodika, atom fluora, hidroksi skupinu, amino, metil ili trifluorometil;
R2c represents a hydrogen atom, a halogen atom, a hydroxy group, C1-6 alkyl which may have any group selected from substituent group a or C1-6 alkoxy which may have any group selected from substituent group a, or when R2a and R2b, or R2b and R2c independently represent a group selected from the group consisting of C1-6 alkyl which may be substituted by a fluorine atom and C1-6 alkoxy which may be substituted by a fluorine atom, they optionally form a 5 to 8-membered ring together with the binding atoms in the indolizine ring; 
c predstavlja atom vodika, atom halogena, hidroksi skupinu, C1-6 alkil koji može imati bilo koju skupinu izabranu iz grupe supstituenata a ili C1-6 alkoksi koji može imati bilo koju skupinu izabranu iz grupe supstituenata a, ili kada R2a i R2b, ili R2b i R2c nezavisno predstavljaju skupinu izabranu iz grupe koja obuhvaća C1-6alkil koji može biti supstituiran atomom fluora i C1-6 alkoksi koji može biti supstituiran atomom fluora, oni po izboru formiraju 5 do 8-eročlani prsten zajedno s veznim atomima u indolizinskom prstenu;
R2d represents a hydrogen atom or a fluorine atom; 
d predstavlja atom vodika ili atom fluora;
An indolizine derivative as claimed in claim 3 or 4, wherein R2a and R2b independently represent any of the following (b1) to (b4): 
Derivat indolizina prema zahtjevu 3 ili 4, gdje R2a i R2b nezavisno predstavljaju bilo što od sljedećeg (b1) do (b4):
R2c represents a hydrogen atom, a halogen atom, a hydroxy group, C1-6 alkyl which may be substituted by a fluorine atom or C1-6 alkoxy which may be substituted by a fluorine atom, or a prodrug thereof, or a pharmaceutically acceptable salt thereof. 
c predstavlja atom vodika, atom halogena, hidroksi skupinu, C1-6 alkil koji može biti supstituiran atomom fluora ili C1-6 alkoksi koji može biti supstituiran atomom fluora, ili prolijek, ili farmaceutski prihvatljiva sol.
An indolizine derivative as claimed in claim 6 or 7, wherein R1a represents a hydrogen atom or a hydroxy group; 
Derivat indolizina prema zahtjevu 6 ili 7, gdje R1a predstavlja atom vodika ili hidroksi skupinu;
A pharmaceutical composition as claimed in claim 13, which is an agent for the prevention or treatment of a disease selected from the group consisting of hyperuricemia, gouty tophus, gouty arthritis, renal disorder associated with hyperuricemia and urinary calculi. A pharmaceutical composition as claimed in claim 14, which is an agent for the prevention or treatment of hyperuricemia. 
Farmaceutska smjesa prema zahtjevu 13, za uporabu u prevenciji ili liječenju bolesti izabrane iz grupe koja obuhvaća hiperurikemiju, giht s kamencima, artritični giht, poremećaj bubrega povezan s hiperurikemijom i urinarni kamenci po izboru za uporabu u prevenciji ili liječenju hiperurikemije, po izboru za uporabu za snižavanje razine urične kiseline u serumu.
The jacketed tube of claim 1 wherein the metal tube comprises incoloy, stainless steel, carbon steel, or galvanized carbon steel. 
Obložena cijev u skladu s patentnim zahtjevom 1, naznačena time što se metalna cijev sastoji od inkoloja, nehrđajućeg čelika, ugljičnog čelika ili galvaniziranog ugljičnog čelika.
The jacketed tube of claim 1 comprising one or more steel ropes within one or more protective jackets surrounding the smooth solid wall metal tube and tear cord wherein a tear cord is positioned next to each steel rope and tube and the steel rope has the same orientation as the tube and is positioned adjacent to the tube within the jacket. 
Obložena cijev u skladu s patentnim zahtjevom 1, naznačena time što sadrži jedno ili više čelične užadi unutar jedne ili više zaštitnih obloga koje okružuju glatku punu stijenku metalne cijevi i žicu za kidanje, gdje se žica za kidanje nalazi uz svako čelično uže i cijev, a čelično uže ima istu orijentaciju kao cijev i nalazi se uz cijev unutar obloge.
The jacketed tube of claim 1 further comprising a jacket of one or more materials of a group consisting of polyethylene, ethylene chlorotrifluoroerthlyene, a thermoplastic elastomer cross linking ethylene propylene diene monomer rubber and polypropylene, perfluoroalkoxy, polyvinylidene fluoride and fluorinated ethylene propylene wherein the material is extruded onto the tube without radiation curing. 
Obložena cijev u skladu s patentnim zahtjevom 1, naznačena time što dodatno sadrži oblogu od jednog ili više materijala iz skupine koju čine polietilen, etilen-klortrifluoretilen, termoplastični elastomerni umreženi etilen-propilen-dien-monomer-kaučuk i polipropilen, perfluoralkoksi, poliviniliden-fluorid i fluorirani etilen-propilen, gdje se materijal ekstrudira na cijev bez stvrdnjavanja uz pomoć zračenja.
The jacketed tube of claim 14 further comprising at least one compression fitting. 
Obložena cijev u skladu s patentnim zahtjevom 14, naznačena time što dodatno sadrži najmanje jednu kompresivnu spojnicu.
The method of claim 17 further comprising placing a second tear cord adjacent to the outer diameter of the protective jacket and covering the first jacket with a second jacket. 
Postupak u skladu s patentnim zahtjevom 17, naznačen time što dodatno sadrži stavljanju druge žice za kidanje uz vanjski promjer zaštitne obloge i prekrivanju prve obloge drugom oblogom.
The use of a compound as defined in Claim 1, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of infections caused by bacteria. 
Uporaba spoja definiranog u patentnom zahtjevu 1, ili njegove farmaceutski prihvatljive soli, za uporabu lijeka za liječenje ili prevenciju zaraza uzrokovanih bakterijama.
Compound for use according to Claim 3, or use according to Claim 4, wherein the infection is caused by a Gram-positive bacterium selected from Staphylococcus spp ., Streptococcus spp ., Propionibacterium spp ., Enterococcus spp ., Bacillus spp ., Corynebacterium spp ., Nocardia spp ., Clostridium spp ., Actinobacteria spp ., and Listeria spp .. 
Spoj za uporabu prema patentnom zahtjevu 3, ili uporabu prema patentnom zahtjevu 4, naznačen time da je zaraza uzrokovana Gram-pozitivnom bakterijom izabranom od Staphylococcus spp., Streptococcus spp., Propionibacterium spp., Enterococcus spp., Bacillus spp., Corynebacterium spp., Nocardia spp., Clostridium spp., Actinobacteria spp. i Listeria spp.
Compound for use according to Claim 3, or use according to Claim 4, wherein the infection is caused by a Gram-negative bacteria selected from Enterobactericeae, Bacteroidaceae, Vibrionaceae, Pasteurellae, Pseudomonadaceae, Neisseriaceae, Rickettsiae, Moraxellaceae, any species of Proteeae, Acinetobacter spp., Helicobacter spp., and Campylobacter spp.. 
Spoj za uporabu prema patentnom zahtjevu 3, ili uporabu prema patentnom zahtjevu 4, naznačen time da je zaraza uzrokovana Gram-negativnom bakterijom izabranom od Enterobactericeae, Bacteroidaceae, Vibrionaceae, Pasteurellae, Pseudomonadaceae, Neisseriaceae, Rickettsiae, Moraxellaceae, bilo koja vrsta Proteeae, Acinetobacter spp., Helicobacter spp., i Capylobacter spp.
A process for making a composition as defined in Claim 2, which process comprises mixing the compound as defined in Claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. 
Postupak za proizvodnju pripravka definiranog u patentnom zahtjevu 2, koji sadrži miješanje spoja kao što je definiran u patentnom zahtjevu 1, ili njegove farmaceutski prihvatljive soli, i farmaceutski prihvatljivog nosača ili razrjeđivača.
A system as claimed in claim 1, characterised in that said system comprises a plurality of said main tubes (10) which are aligned and fixed to a plurality of said first (13) and said second posts (13). 
Sustav prema zahtjevu 1, naznačen time, da spomenuti sustav obuhvaća veći broj navedenih glavnih cijevi (10) koje su poredane u nizu i pričvršćene na veći broj navedenih prvih podupirača (13) i navedenih drugih podupirača (13).
A system as claimed in claim 1, characterised in that said first post (13) and said second post (13) have a height greater than 3 m and preferably greater than 4 m. 
Sustav prema zahtjevu 1, naznačen time, da prvi podupirač (13) i drugi podupirač (13) imaju visinu veću od 3 m i poželjno veću od 4 m.
Use of phytopharmaceutical compositions comprising an extract of Vitis vinifera seeds or marcs containing seeds as the active ingredient, in the treatment and/or prevention of infections by pathogenic organisms of plants. 
Upotreba fitofarmaceutskih pripravaka koji sadrže ekstrakt sjemenki Vitis vinifera ili ostatka tještenja koji sadrži sjemenke kao aktivni sastojak, naznačena time da je za liječenje i/ili sprječavanje infekcija patogenih organizama u biljkama.
A crate, comprising: 
Sanduk koji obuhvaća:
The crate of claim 1, wherein the crate is formed of plastic. The crate of claim 1 or 2, wherein the crate is provided for receiving and/or transporting foods, for example fruits, vegetables, meat and the like. 
Sanduk prema zahtjevu 1 ili 2, naznačen time, da je taj sanduk pripremljen za prihvat i/ili prijenos prehrambenih namirnica, primjerice voća, povrća, mesa i sličnoga.
R3a represents a hydrogen atom or a fluorine atom; and substituent group a has the same meaning as described in claim 1, or a prodrug thereof, or a pharmaceutically acceptable salt thereof in which "prodrug" means a compound wherein one or more carboxy groups of a compound represented by the above general formula (Ia) is substituted by a group forming a prodrug, in which the group forming a prodrug is selected from the group consisting of C1-6 alkyl, C1-6 alkyl-COO-C1-6 alkylene, C1-6 alkyl-OCOO-C1-6 alkylene, C3-8 cycloalkyl-OCOO-C1-6 alkylene, mono(di)hydroxy C1-6 alkyl, mono(di)hydroxy C1-6 alkyl-OCOO-C1-6 alkylene, C1-6 alkoxy C1-6 alkoxy C1-6 alkyl, mono(di)C1-6 alkylamino C1-6 alkyl, 3 to 8-membered heterocycloalkyl C1-6 alkyl, and C1-6 alkyl-OCO-amino C1-6 alkylene. 
a predstavlja atom vodika ili atom fluora; i grupa supstituenata a ima isto značenje kako je opisano u zahtjevu 1, ili njihov prolijek, ili njihovu farmaceutski prihvatljivu sol, pri čemu "prolijek" označava spoj u kojem je jedna ili više karboksi skupina spoja predstavljenog gore općom formulom (Ia) supstituirana skupinom koja daje prolijek, gdje se skupina koja daje prolijek izabire iz grupe koja obuhvaća C1-6 alkil, C1-6 alkil-COO-C1-6 alkilen, C1-6 alkil-OCOO-C1-6 alkilen, C3-8 cikloalkil-OCOO-C1-6 alkilen, mono(di)hidroksi C1-6 alkil, mono(di)hidroksi C1-6 alkil-OCOO-C1-6alkilen, C1-6 alkoksi C1-6 alkoksi C1-6 alkil, mono(di)C1-6 alkilamino C1-6 alkil, 3 do 8-eročlani heterocikloalkil C1-6 alkil, i C1-6 alkil-OCO-amino C1-6 alkilen.